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Abstract: AIMS To critically evaluate the clinical implications of the use of non-fasting rather than
fasting lipid profiles and to provide guidance for the laboratory reporting of abnormal non-fasting or
fasting lipid profiles. METHODS AND RESULTS Extensive observational data, in which random non-
fasting lipid profiles have been compared with those determined under fasting conditions, indicate that
the maximal mean changes at 1-6 h after habitual meals are not clinically significant [+0.3 mmol/L (26
mg/dL) for triglycerides; -0.2 mmol/L (8 mg/dL) for total cholesterol; -0.2 mmol/L (8 mg/dL) for LDL
cholesterol; +0.2 mmol/L (8 mg/dL) for calculated remnant cholesterol; -0.2 mmol/L (8 mg/dL) for
calculated non-HDL cholesterol]; concentrations of HDL cholesterol, apolipoprotein A1, apolipoprotein
B, and lipoprotein(a) are not affected by fasting/non-fasting status. In addition, non-fasting and fasting
concentrations vary similarly over time and are comparable in the prediction of cardiovascular disease.
To improve patient compliance with lipid testing, we therefore recommend the routine use of non-fasting
lipid profiles, whereas fasting sampling may be considered when non-fasting triglycerides are >5 mmol/L
(440 mg/dL). For non-fasting samples, laboratory reports should flag abnormal concentrations as triglyc-
erides ￿2 mmol/L (175 mg/dL), total cholesterol ￿5 mmol/L (190 mg/dL), LDL cholesterol ￿3 mmol/L
(115 mg/dL), calculated remnant cholesterol ￿0.9 mmol/L (35 mg/dL), calculated non-HDL cholesterol
￿3.9 mmol/L (150 mg/dL), HDL cholesterol ￿1 mmol/L (40 mg/dL), apolipoprotein A1 ￿1.25 g/L (125
mg/dL), apolipoprotein B ￿1.0 g/L (100 mg/dL), and lipoprotein(a) ￿50 mg/dL (80th percentile); for
fasting samples, abnormal concentrations correspond to triglycerides ￿1.7 mmol/L (150 mg/dL). Life-
threatening concentrations require separate referral for the risk of pancreatitis when triglycerides are
>10 mmol/L (880 mg/dL), for homozygous familial hypercholesterolemia when LDL cholesterol is >13
mmol/L (500 mg/dL), for heterozygous familial hypercholesterolemia when LDL cholesterol is >5 mmol/L
(190 mg/dL), and for very high cardiovascular risk when lipoprotein(a) >150 mg/dL (99th percentile).
CONCLUSIONS We recommend that non-fasting blood samples be routinely used for the assessment
of plasma lipid profiles. Laboratory reports should flag abnormal values on the basis of desirable con-
centration cutpoints. Non-fasting and fasting measurements should be complementary but not mutually
exclusive.
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Advances in Lipid Testing:
A Practical Step Forward
Neil J. Stone*
Measuring lipids and lipoproteins has been an important
focus for both clinical chemistry and clinical medicine for
over 75 years.Measurements from analytical ultracentrif-
ugation (1 ) to preparative ultracentrifugation (2 ) pro-
vided invaluable insights, but were not suited for day-to-
day clinical practice. Fredrickson, Levy, and Lees (3 )
used paper electrophoresis to stimulate clinical recogni-
tion in five major patterns of plasma lipoprotein excess.
Known as type I, II (IIa and IIb), III, IV, and V, they
represented distinctive phenotypes, not genotypes. The
shorthand notations, however, provided insight into an
individual patient’s lipoprotein disorder, whether due to
acquired and/or genetic causes.
Yet a non–ultracentrifuge-based methodology was
needed to quantify LDL cholesterol (LDL-C) concentra-
tions in clinical practice (1 ). The Friedewald formula
allowed LDL-C determination by using a fasting total
cholesterol, HDL-C, and triglycerides/5 (when triglycer-
ide concentration was expressed in mg/dL) with the ca-
veats that it could not be used if triglycerides were400
mg/dL (4.5 mmol/L) or the rare type III abnormality was
present (4 ). This formula continues in widespread use
today, but up until the recent guidance from this consen-
sus panel has required a fasting lipid sample.
In this issue of Clinical Chemistry, a prominent in-
ternational panel argues persuasively that fasting is not
routinely required for lipid determinations (5 ). The
panel notes that nonfasting lipid panels provide practical
benefits for clinician, patient, and clinical laboratory
alike; have been used successfully in population cohort
studies as well as randomized controlled trials of statins;
and have been used in Denmark since 2009. They show
data to indicate similar prognostic value for mean values
for lipids whether fasting or not. They provide guidance
for when a fasting lipid panel may be required and list
thresholds for interpreting nonfasting lipids and lipopro-
teins for laboratory reports for patient and clinician.
Is nonfasting an advantage over traditional lipid
thinking? It is important to note that although the 2013
American College of Cardiology/American Heart Asso-
ciation cholesterol guidelines preferred fasting lipids,
they acknowledged that nonfasting lipids could be used.
They noted in patients with nonfasting concentrations of
non–HDL-C220 mg/dL (5.7 mmol/L) or triglycer-
ides 500 mg/dL (5.7 mmol/L) that a fasting sample
was needed to inquire into an underlying genetic disorder
(6 ). Moreover, the lipid inputs for risk estimation in the
American College of Cardiology/American Heart Asso-
ciation cholesterol guideline risk estimator use total cho-
lesterol andHDL-C, which can be obtained in a nonfast-
ing state (7 ). Both an editorial and a recent article
acknowledged, however, that whether fasting or nonfast-
ing lipids are recommended, the choice of the specimen
type depends on the question posed by the clinical situ-
ation (8, 9 ).
Although there is no disagreement regarding routine
nonfasting lipids for atherosclerotic cardiovascular dis-
ease risk determination, there still are situations for which
fasting is preferred or may be required. This list includes
monitoring patients with severe hypertriglyceridemia
(440 mg/dL or5 mmol/L) and patients with hyper-
triglyceridemia followed in a lipid clinic, monitoring
triglycerides in individuals recovering from hyperlipid-
emic pancreatitis, and establishing a triglyceride assess-
ment baseline before startingmedications that can trigger
severe hypertriglyceridemia and risk of acute pancreatitis.
Common examples of these medications include ste-
roids, estrogens, tamoxifen, retinoic acid for acne, or
L-asparaginase used in chemotherapy. Fasting lipids can
make sense if a fasting blood sample was needed for other
reasons. Consider patients who require a fasting blood
glucose. This sample may be required to monitor the
metabolic syndrome or follow individuals on statin ther-
apy who develop increased fasting blood glucose concen-
trations. Using data from the JUPITER (Justification for
the Use of Statins in Prevention: an Intervention Trial
Evaluating Rosuvastatin) randomized controlled trial, in-
vestigators noted progression to diabetes was more likely
to occur if the statin-treated individual had major diabe-
tes risk factors such as fasting blood glucose100mg/dL
(5.5 mmol/L), hemoglobin A1c 6.0% (42 mmol/
mol), body mass index 30 kg/m2, or metabolic syn-
drome factors, whereas it was unlikely if they did not
(10 ).
Although the panel presents data showing concor-
dance with mean values for LDL-C measured by the
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Friedewald formula in fasting and nonfasting samples, a
note of caution should be raised by those who use fixed
LDL-C targets for clinical decision-making. This sce-
nario is not a concern for the National Institute for
Health and Care Excellence–UK guidelines (11 ) or the
US guidelines (6 ), which did not treat to fixed targets. It
is a potential concern, however, for clinicians who follow
the current European Atherosclerosis Society/European
Society of Cardiology guidelines (as noted in Box 2 of
the joint consensus statement) and use 70 mg/dL (1.8
mmol/L ) as a target for high-risk patients (12 ). Martin et
al. (13 ) in a sample of1 million patients noted that the
Friedewald equation tended to underestimate LDL-C
when triglyceride concentrations were 150 mg/dL
(1.7 mmol/L). This result most likely occurred when
triglyceride concentrations exceeded 200 mg/dL (2.25
mmol/L). Thus the use of nonfasting samples along with
guidelines that advocate decision-making based on fixed
targets could affect therapy decisions. Finally, many hos-
pitals and clinics are in close proximity to restaurants. To
minimize variability, patients should be counselled to
avoid high-fat meals on the day of the visit.
In summary, the panel makes a strong case for rou-
tine nonfasting lipids. This is especially so for atheroscle-
rotic cardiovascular disease risk assessment. This guid-
ance alone should reduce morning congestion in clinical
laboratories and allow the patient seen in an afternoon
clinic to avoid having to return for fasting assessment.
But as this report indicates, there are situations in those
with increased triglycerides for which fasting is preferred
and clinicians might benefit from point-of-care prompts
to be sure they are understood. Finally, nonfasting lipids
should be identified as such in the electronic medical
record database. This step will aid clinical recognition of
older data for which fasting was the norm and the newer
nonfasting data. It will also aid research queries of the
electronic medical record to provide further insights that
hopefully will improve lipid thinking.
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